Cardiac function and cardiopulmonary performance in patients
after treatment for non-Hodgkin's lymphoma

J 2006

Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL et. al.

Basic information

Original name

Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma

Name in Czech

Srdeční funkce a kardiopulmonární výkon u pacientů po léčbě non-Hodkingova lymfomu

Authors

ELBL, Lubomír (203 Czech Republic, guarantor), Ingrid VÁŠOVÁ (203 Czech Republic), Iva TOMÁŠKOVÁ (203 Czech Republic), František JEDLIČKA (203 Czech Republic), Milan NAVRÁTIL (203 Czech Republic), Zdeněk POSPÍŠIL (203 Czech Republic) and Jiří VORLÍČEK (203 Czech Republic)

Edition

Neoplasma, SLOVAKIA, VEDA, SLOVAK ACADEMY SCIENCES, 2006, 0028-2685

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Slovakia

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.247

RIV identification code

RIV/00216224:14310/06:00025786

Organization unit

Faculty of Science

UT WoS

000236399400014

Keywords in English

cardiotoxicity; doxorubicin; non-Hodgkin's lymphoma

Abstract

ORIG CZ

V originále

Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin's lymphoma, is associated with the presence of an early impairment of cardiac function. Forty seven patients were prospectively examined (27 male and 20 female) aged 49 +/- 14 years who were treated with CHOP regimen. Rest echocardiography was performed at baseline and one-year control. Cardiopulmonary exercise test was carried out at one-year control examination. The ejection fraction (EF), parameters of diastolic function, myocardial performance index (MPI), and pVO(2) were used as parameters of cardiopulmonary performance. The cumulative dose (CD) of doxorubicin was 277 +/- 56 (300 mg/m(2)) was given. The baseline EF 64 +/- 5% (64%) decreased to 58 +/- 7% (57%) at the one-year control (p<0.0001). 23% of patients exhibited a drop in EF >10% during the follow-up. 43% revealed a pathologically increased value of MPI >0.55, and 47% impaired diastolic function compared to the baseline values, respectively. 21% of patients exhibited a decrease of pVO(2) <20 ml/kg/min, and 17% pVO(2) <80% of the reference value, respectively. None of the patients developed signs of heart failure. The Doppler parameters of both diastolic and global LV function were the most affected measures and significantly influenced the cardiopulmonary performance. Multivariate analysis showed that CD >= 300 mg/m(2) (OR=8.08; p<0.05) and the presence of risk factors (OR=9.48; p<0.008) are the best predictors of cardiotoxicity. The results show that subclinical cardiac impairment was frequent in patients receiving the CHOP regimen with safe cumulative doses of doxorubicin. The value of described changes for the development of heart failure has to be assessed during the prospective follow-up.

In Czech

Závěry roční prospektivní studie: režim CHOP (cyclophosphamide, doxorubicin, vincristin a prednisone) s bezpečným dávkováním doxorubicinu často způsobuje subklinické zhoršení srdeční funkce.

Links

LC06024, research and development project

Name: Centrum Jaroslava Hájka pro teoretickou a aplikovanou statistiku

Investor: Ministry of Education, Youth and Sports of the CR, Jaroslav Hájek Center for Theoretical and Applied Statistics

Citovat

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL, Zdeněk POSPÍŠIL and Jiří VORLÍČEK. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. Neoplasma. SLOVAKIA: VEDA, SLOVAK ACADEMY SCIENCES, 2006, vol. 53, No 2, p. 174-181. ISSN 0028-2685.

@article{759112,
   author = {Elbl, Lubomír and Vášová, Ingrid and Tomášková, Iva and Jedlička, František and Navrátil, Milan and Pospíšil, Zdeněk and Vorlíček, Jiří},
   article_location = {SLOVAKIA},
   article_number = {2},
   keywords = {cardiotoxicity; doxorubicin; non-Hodgkin's lymphoma},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma},
   volume = {53},
   year = {2006}
}

TY  - JOUR
ID  - 759112
AU  - Elbl, Lubomír - Vášová, Ingrid - Tomášková, Iva - Jedlička, František - Navrátil, Milan - Pospíšil, Zdeněk - Vorlíček, Jiří
PY  - 2006
TI  - Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma
JF  - Neoplasma
VL  - 53
IS  - 2
SP  - 174-181
EP  - 174-181
PB  - VEDA, SLOVAK ACADEMY SCIENCES
SN  - 00282685
KW  - cardiotoxicity
KW  - doxorubicin
KW  - non-Hodgkin's lymphoma
N2  - Authors conducted a one-year prospective study to determine whether CHOP regimen (cyclophosphamide, doxorubicin, vincristin, and prednisone), used in the treatment of aggressive non-Hodgkin's lymphoma, is associated with the presence of an early impairment of cardiac function. Forty seven patients were prospectively examined (27 male and 20 female) aged 49 +/- 14 years who were treated with CHOP regimen. Rest echocardiography was performed at baseline and one-year control. Cardiopulmonary exercise test was carried out at one-year control examination. The ejection fraction (EF), parameters of diastolic function, myocardial performance index (MPI), and pVO(2) were used as parameters of cardiopulmonary performance. The cumulative dose (CD) of doxorubicin was 277 +/- 56 (300 mg/m(2)) was given. The baseline EF 64 +/- 5% (64%) decreased to 58 +/- 7% (57%) at the one-year control (p<0.0001). 23% of patients exhibited a drop in EF >10% during the follow-up. 43% revealed a pathologically increased value of MPI >0.55, and 47% impaired diastolic function compared to the baseline values, respectively. 21% of patients exhibited a decrease of pVO(2) <20 ml/kg/min, and 17% pVO(2) <80% of the reference value, respectively. None of the patients developed signs of heart failure. The Doppler parameters of both diastolic and global LV function were the most affected measures and significantly influenced the cardiopulmonary performance. Multivariate analysis showed that CD >= 300 mg/m(2) (OR=8.08; p<0.05) and the presence of risk factors (OR=9.48; p<0.008) are the best predictors of cardiotoxicity. The results show that subclinical cardiac impairment was frequent in patients receiving the CHOP regimen with safe cumulative doses of doxorubicin. The value of described changes for the development of heart failure has to be assessed during the prospective follow-up.
ER  -

ELBL, Lubomír, Ingrid VÁŠOVÁ, Iva TOMÁŠKOVÁ, František JEDLIČKA, Milan NAVRÁTIL, Zdeněk POSPÍŠIL and Jiří VORLÍČEK. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma. \textit{Neoplasma}. SLOVAKIA: VEDA, SLOVAK ACADEMY SCIENCES, 2006, vol.~53, No~2, p.~174-181. ISSN~0028-2685.

Detailed Information on Publication Record